Comments
Alembic Pharmaceuticals Ltd, a Vadodara-based pharma player, posted a 24 per cent jump in standalone net profit for the first quarter ended June 2014 at Rs 61 crore against Rs 49 crore reported in the corresponding period last year.
On standalone basis, the company reported total income from operations at Rs 482 crore against Rs 427 crore in the same period a year ago.
On consolidated basis, the company’s net profit increased by 39 per cent to Rs 64 crore against Rs 47 crore. Total income from the operations stood at Rs 494 crore for the quarter against Rs 427 crore in the same quarter last year.
The company's domestic branded formulations sales increased by 16 per cent for the quarter at Rs 223 crore against Rs 192 crore for the same period a year ago. Specialty and Acute segments grew by 25 per cent and 4 per cent respectively during the quarter, the company said in a statement after announcement of the results.
The company's international generic formulations sales jumped 33 per cent for the quarter at Rs 114 crore against Rs 85 crore in corresponding quarter last year.
The company filed three ANDAs during the quarter taking the total cumulative ANDA filing for the company to 64. During the quarter three ANDA approvals were received, taking the cumulative ANDA/NDA approvals to 35 (including 5 tentative approvals).
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.